PHI-301

PHI-301 is a **small-molecule focal adhesion kinase inhibitor** being developed by **Pharos I&Bt** for oncology indications. Public pipeline references describe it as an early-stage discovery or preclinical program targeting **focal adhesion kinase** to inhibit aberrant cell-extracellular matrix signaling involved in tumor invasion and metastasis. Available public information is limited, but company and commercial pipeline sources associate PHI-301 primarily with **difficult-to-treat lung cancer**, with some third-party pipeline listings also mentioning **ovarian cancer** and **prostate cancer** as potential development contexts.